Abstract: Organic electroluminescent (OEL) devices are proposed herein to be fabricated either as a light source or a heating source for biochips. Under the proposed approach, an OEL-emitting member is fabricated as the substrate of the biochip on which the biological samples, such as DNA, proteins and other related small molecules, are processed for the desired applications, including but not limited to, analysis of biological molecules, such as electrophoretic separation, PCR amplification and hybridization.

Abstract: A system is provided wherein a plug flow reactor is used to make combinatorial libraries of materials. Examples of plug flow reactors include stirred tube reactors, extruders, and static mixers.

Abstract: A method for testing cleaning effect of a compound or compositions is disclosed.

Abstract: Devices and use thereof, the device comprising a filter and a means for region specific compression of the filter. Alteratively, the device comprises a filter; a region containing the filter; a fluid access port to the region containing the filter; a fluid egress port from the region containing the filter; and a lateral fluid flow path through the filter connecting the fluid access port to the fluid egress port.

Abstract: An apparatus is provided for simultaneous processing of multiple fluid samples. The apparatus comprises a multiple well plate for holding a plurality of sample reservoirs for simultaneous processing of multiple samples. The wells are configured in the plate in staggered rows. The well plate is dimensioned to be compatible with a vacuum manifold or positive pressure system either as a stand-alone unit or in conjunction with a separate fluid handling system. The apparatus may further comprise a sample collection plate having the same number of wells as the multiple well plate. The wells in the samples collection plate are arranged in the same staggered configuration as the wells in the well plate and are sized for holding sample collection vials. When the well plate and sample collection plate are assembled in a manifold, the vials in the sample collection plated are aligned directly beneath the sample exits of corresponding sample reservoirs in the well plate.

Abstract: This invention is related to an enhanced heat conductive device for supply device of hydrogen source of a fuel cell. The supply device comprises: at least one pressurized bottled filled with metal hydride and having an outer diameter. The enhanced heat conductive device comprises: a metal shell configured to an elongated, cylindrical column having an inner diameter, and at least one expandable rib, longitudinally extended along a length direction of and integrally formed with the metal shell. The outer diameter of the pressurized bottle is slightly greater than the inner diameter of the metal shell, such that when the pressurized bottle is inserted through the metal shell, the pressurized bottle will force expansion of the rib resulting in close contact between the metal shell and the pressurized bottle. This invention further discloses supply device of hydrogen source having such an enhanced heat conductive device.

Abstract: The present invention relates to industrial high relative viscosity (RV) filaments, such as, for use in papermaking machine felts and other staple fiber applications. The invention is further directed to apparatus and processes for solid phase polymerization (SPP) of polyamide flake suitable for use, such as, in remelting and then spinning the industrial high RV filaments. The invention is also directed to processes for melt phase polymerization (MPP) of molten polymer for making the filaments.

Abstract: Regenerative oxidizer including an entrapment chamber and damper assembly, as well as a method of oxidizing volatile organic compounds in a gas using such apparatus. To improve the VOC destruction efficiency and eliminate opacity issues resulting from heat exchange matrix regeneration, untreated fluid can be diverted away from the oxidizer exhaust stack and directed into a “holding vessel” or VOC entrapment chamber. The assembly utilizes a single damper in order to divert the exhaust flow from the oxidizer either to exhaust or to the entrapment chamber. The entrapment chamber preferably has a modular construction, which facilitates expanding or decreasing the volume of the chamber. The design facilitates installation and can be retrofitted on existing equipment. The damper diverts the flow of gas with minimal or no negative impact on the process flow.

Abstract: A process is described for the purification of organometallic compounds or heteroatomic organic compounds from oxygen, water and from the compounds deriving from the reaction of water and oxygen with the organometallic or heteroatomic compounds whose purification is sought, comprising the operation of contacting the organometallic or heteroatomic compound to be purified, in the liquid state or in form of vapor, pure or in a carrier gas, with a catalyst based on iron and manganese supported on zeolites, and optionally also with one or more gas sorber materials selected among hydrogenated getter alloys and palladium deposited on a porous support.

Abstract: An apparatus for generating an effective concentration of ozone for killing bacteria, viruses and other harmful microorganisms includes a housing having an ozone chamber defining an enclosed space for containing elevated concentrations of ozone. The ozone chamber includes ports providing access to the interior of the ozone chamber. A second chamber of the apparatus houses an ozone reactor. A programmable control circuit operates both the ozone reactor and a pump for directing ambient air to the ozone reactor. The control circuit includes a motion detector mounted in the ozone chamber for activating the ozone generator of the invention and initiating the generation of ozone directed into the ozone chamber of the apparatus of the invention.

Abstract: A process for hydroprocessing a hydrocarbon feed with a known flow rate of hydrogen-containing gas and a volume of catalyst, includes the steps of providing a hydrocarbon feed having an initial characteristic; feeding the hydrocarbon feed and a first portion of the hydrogen-containing gas cocurrently to a first hydroprocessing zone containing a first portion of the catalyst so as to provide a first hydrocarbon product; providing an additional hydroprocessing zone containing a remainder of the catalyst; feeding the first hydrocarbon product cocurrently with a remainder of the hydrogen-containing gas to the additional hydroprocessing zone so as to provide a final hydrocarbon product having a final characteristic which is improved as compared to the initial characteristic, wherein the first portion of the hydrogen-containing gas is between about 30 and about 80% vol. of the known flow rate of the hydrogen-containing gas, and the first portion of the catalyst is between about 30 and about 70% wt.

Abstract: A method is provided to inject steam into a hydrocarbon effluent passing through a transfer line exchanger (TLE) of a hydrocarbon cracking furnace to reduce the formation of a coke material on the TLE tubesheet. The apparatus that injects the steam is also provided to deliver a distributed steam flow in the low resonance area of the TLE cone.

Abstract: The present invention provides a system for, and method of, performing various liquid-liquid contacting operations such as solvent extraction, stripping, scrubbing, washing, re-extraction and reacting in a single, integrated column. The ability of the integrated column, which is based on the intermediate decanter, of the present invention, to perform the entire operation of solvent extraction plant in a single column has many technical, economical, ecological and operational safety advantages. Investment costs significantly decrease due to the decrease in the number of columns, decanters, and auxiliary equipment, spare parts, materials inventories and the requisite area for the plant relative to a standard prior art plant. Operating and maintenance costs also decrease due to less pumping between columns and less equipment in operation.

Abstract: An improved method for making polyphosphoric acid from phosphoric acid includes the steps of introducing a first phosphoric acid feed stream into the top end of a packed column, introducing a second phosphoric acid feed stream into a stream of hot air to form a stream of hot air and acid, introducing the stream of hot air and acid into the bottom end of the column, and polymerizing phosphoric acid of the first and second phosphoric acid feed streams to make polyphosphoric acid. By-product phosphoric acids containing organic contaminants may be substituted for all or part of the phosphoric acid stream being introduced into the bottom end of the column to allow recovery of the phosphorus values of the by-product phosphoric acids.

Abstract: Compositions including oxycarbide-based nanorods and/or carbide-based nanorods and/or carbon nanotubes bearing carbides and oxycarbides and methods of making the same are provided.

Abstract: A method and apparatus for separating gas mixtures containing synthesis gas (syngas) into separate streams of wet hydrogen containing significantly reduced amounts of CO2 and CO, with the CO2 being “sequestration ready” and containing less than 1% fixed gases. In the preferred embodiment, a mixture of limestone and iron oxide circulates between two fluidized beds whereby one bed is fluidized with a gas containing syngas, while the other bed is fluidized with a gas containing steam and oxygen. As the fluidizing gas containing syngas passes through the bed, the CO2 reacts with CaO to form CaCO3. Virtually all of the CO is removed by a water gas shift reaction, forming hydrogen and CO2, with the remainder being removed by reaction with the iron oxide, reducing Fe2O3 to FeO. Some hydrogen is also removed by reaction with the iron oxide, reducing Fe2O3 to FeO, while the remainder of the hydrogen passes through the fluid beds, leaving in a purified state, i.e., PEM fuel cell quality.

Abstract: The present invention concerns a method for the production of a titanium-containing zeolite by: (a) combining a hydrolyzable silicon compound and a hydrolyzable titanium compound; (b) adding a basic quaternary ammonium compound in an aqueous medium to the mixture from (a) and hydrolysing the reaction mixture at a temperature in the range from 0° C. to 100° C. to form a synthesis sol; then (c) heating the synthesis sol to a temperature in the range from 150° C. to 190° C.; and (d) crystallizing the synthesis sol at this temperature, characterized in that the heating-up time in step (c) is less than 240 min.

Abstract: Sodium nonatitanate compositions, a method using the composition for recovery of 82Sr from irradiated targets, and a method using the composition for generating 82Rb. The sodium nonatitanate materials of the invention are highly selective at separating strontium from solutions derived from the dissolution of irradiated target materials, thus reducing target processing times. The compositions also have a very low affinity for rubidium, making it an ideal material for use as a 82Rb generator. Sodium nonatitanate materials of this type both improve the recovery of 82Sr and provide a safer, more effective 82Rb generator system.

Abstract: In a human or animal joint, specific objects serve as indicators, or biomarkers, of joint disease. In a three-dimensional image of the joint, the biomarkers are identified and quantified. Multiple three-dimensional images can be taken over time, in which the biomarkers can be tracked over time. Statistical segmentation techniques are used to identify the biomarker in a first image and to carry the identification over to the remaining images.

Abstract: A medicinal formulation is disclosed. The formulation comprises (a) a salt/ion pair of a protein peptide medicament; and (b) a fluid carrier for containing said medicament.

Abstract: Methods and formulations for delivery of macromolecules, such as proteins, polysaccharides, and nucleic acids, are disclosed, where the macromolecule is dissolved or dispersed in a low toxicity organic solvent which can be aerosolized for delivery to a patient's lungs by inhalation. Optionally, appropriate solubility enhancers are also present in the formulations composition.

Abstract: The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to the delivery of drug containing aerosols having particles with a mass median aerodynamic diameter less than 1&mgr; for inhalation therapy. In a composition aspect of the present invention the drug containing aerosol comprises particles having a mass median aerodynamic diameter between 10 nm and 1&mgr;. Preferably, the particles have a mass median aerodynamic diameter between 10 nm and 900 nm. More preferably, the particles have a mass median aerodynamic diameter between 10 nm and 800 nm, 10 nm and 700 nm, 10 nm and 600 nm, 10 nm and 500 nm, 10 nm and 400 nm, 10 nm and 300 nm, 10 nm and 200 nm, or 10 nm and 100 nm.

Abstract: An aerosolization device comprises a chamber adapted to contain a powder pharmaceutical formulation, a lid at least partially covering the chamber, at least one piercing element forcible through the lid to provide access to the powder pharmaceutical formulation, and a shapeable surface extending from the chamber, the shapeable surface being adapted to undergo a shape change to form a conduit. The powder pharmaceutical formulation may be extracted from the chamber by a user inhaling through the conduit. In another version, the lid is removable from the chamber without the need for a piercing element.

Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.

Abstract: Disclosed is a self-treatment process and system for periodontal patients with gingival detachment of about 3 mm and greater comprising regularly removing biofilms from various supragingival, interproximal and subgingival surfaces, wherein “soft abrasives” are physically worked into the biofilms using toothbrushing, proxy brushing and flossing. The process is also used to help control those inflammation related substances resulting from gum disease that are associated with heart disease.

Abstract: Orthodontic remedies containing parathyroid hormone (PTH) or one or more PTH derivatives as the active ingredient(s).

Abstract: The present invention provides a lipstick composition which drastically improves the color development and also is superior in terms of spreadability, gloss, and long-lastingness

Abstract: Hair treatment compositions comprising a surfactant, PTFE particles, and a cationic polymer The invention also provides for use of a cationic polymer as a deposition aid for PTFE particles dispersed in an aqueous hair treatment composition.

Abstract: A cosmetic preparation in gel form is described which contains undissolved, water-swollen polymer particles and at the interface with gaseous substances forms reversibly a grainy, uneven, light-scattering surface and at the interface with solids forms reversibly a smooth, level, non-light-scattering surface. Preferred gel formers are superabsorbing polymers. A preferred use is the hair-end protection in permanent wave treatment.

Abstract: A hair cosmetic which can impart, to hairs, flexibility, smoothness and oily feeling when the hairs are wetted and smoothness, softness and combing easiness after the hairs are dried are provided, the hair cosmetic comprising an amine represented by the formula (I):

Abstract: The invention relates to cationic compounds and triester compounds to be used for preparation of compositions, which preferably can be in the form of lotions, creams, powders, oils, foams and the like, and be applied to the skin to prevent or reduce or treat skin rash or diaper rash resulting from lypolytic dermatitis. The compositions of the invention can also be applied to diapers, incontinent-pads, wipes and the like. The invention also relates to the use of such a composition to prevent or reduce such a skin rash and a process for reducing the enzyme activity enzymes which are deactivated when the pH is reduced, such as lipase enzymes present on external skin.

Abstract: Biological tissue adhesives can be in the form of a gel that is applied to biological tissue as a “glue” or supported on a backing or substrate to form an article such as a self-sticking patch or pad. Adhesive articles can include such biological tissue adhesives or be functionalized to directly adhere to biological tissue without the biological adhesive.

Abstract: Polyanhydrides which degrade into biologically active salicylates and alpha-hydroxy acids and methods of using these polyanhydrides to deliver the salicylates and alpha-hydroxy acids to a host are provided.

Abstract: New methods for the treatment of human disease are provided. IGFBP-3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP-3 alone at the maximum practicable dose has no measurable beneficial effect on the disease condition.

Abstract: This invention provides methods and compositions for caspase-induced apoptosis. Chimeric proteins are provided that target cells in which apoptosis is to be induced. The chimeric proteins of this invention activate endogenous caspase or provide caspase units that cause cell death. Methods are provided for the use of the chimeric proteins of this invention for in vivo and ex vivo therapies to treat pathological conditions.

Abstract: The present invention relates to compositions comprising compounds which augment activated immune cells, such as T-cells, dendritic cells and natural killer (“NK”) cells, and methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising the administration of said compositions to said subject. In particular, the present invention relates to methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising administrating to said subject one or more compounds that activate one or more cytokine receptors and one or more compounds that activate one or more co-stimulatory molecules expressed by activated immune cells.

Abstract: The present invention relates to in vivo and in vitro methods for controlling proliferation of glucose regulated insulin-producing beta cells by modulating the expression or the activity of the cyclin-dependent kinase inhibitor p57Kip2. The invention further provides recombinant glucose regulated insulin-producing beta cell or cell-line having controlled proliferation and compositions and uses thereof in methods for treatment of diabetes type I, diabetes type II and hyperinsulinism of infancy.

Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.

Abstract: The present invention provides methods of enhancing the immune response to an immunogen and to compositions for use in these methods. In particular the present invention provides a DNA molecule for use in raising an immune response to an antigen. The DNA molecule includes a first sequence encoding a targeting molecule, a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerisation or multimerisation of the product encoded by the DNA molecule.

Abstract: The invention pertains to a gene therapeutic nucleic acid working model containing a regulatory nucleic acid sequence of the 5′ end myosin light chain 2 gene (MLC 2) of the heart that is functionally connected to a nucleic acid, which is encoded for a therapeutically effective gene product, an antisense nucleic acid, or a ribosome, as well as a process for its production and application for the gene therapeutic treatment of heart disease.

Abstract: The invention includes methods for treating or reducing the risk of inflammation in a patient which comprises treating the patient with an inhibitor of activated thrombin activatable fibrinolysis inhibitor. Such diseases include but are not limited to nephritis, systemic lupus erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis. The invention includes methods for treating or reducing the risk of pain in a patient which comprises treating the patient with an inhibitor of activated thrombin activatable fibrinolysis inhibitor.

Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma.

Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.

Abstract: Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID NO:25 and 27 (HumG); SEQ ID NO:29 and 31 (HumH); and SEQ ID NO:33 and 35 (HumI). Subsequences of the humanized antibodies capable of binding an ICAM-1 epitope are also provided. Methods of inhibiting pathogen infection (e.g., HRV) of a cell employing humanized antibodies capable of binding an ICAM-1 epitope are further provided.

Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.

Abstract: A humanized specific monoclonal antibody or antibody fragment, especially a B-cell specific antibody or antibody fragment, is engineered to contain a glyxosylation site in the non-Fc constant region. The glycosylated antibody is useful for diagnosis and/or therapy whenever a targeting antibody or fragment is used, especially for B-cell malignancies. The carbohydrate moiety allows conjugation of labeling or therapeutic agents of increased size, without affecting the binding affinity or specificity of the antibody.

Abstract: Immune stimulatory amounts of hematopoietic colony stimulating factors are administered to patients with inflammatory bowel disease. The factors include G-CSF and GM-CSF. These factors induce and maintain remission of the disease and its manifestations, whether within the intestine or without.

Abstract: The invention provides methods of detection, prevention, amelioration, and treatment for angiogenesis, including angiogenesis associated with colon cancer and glioma. The methods comprise the use of an anti-A2B antibody.

Abstract: The invention provides methods and compositions for alleviating the symptoms of neuropathic conditions with a pharmaceutical composition including an effective amount of anti-glutamic acid decarboxylase (anti-GAD) antibodies.

Abstract: A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the specific cell type; a linker which is acted upon by a molecule which is present at an effective concentration in the environs of the specific cell type; and a drug or an agent to be delivered to the specific cell type. In particular, a drug complex for delivering a cytotoxic drug to prostate cancer cells, comprising a targeting carrier molecule which is selectively delivered to prostate tissue, bone or both; a peptide which is a substrate for prostate specific antigen; and a cytotoxic drug which is toxic to androgen independent prostate cancer cells.